Der Markt für monoklonale Antikörper soll von 111,01 Milliarden US-Dollar im Jahr 2021 bis 2028 auf 243,05 Milliarden US-Dollar steigen; es wird erwartet, dass es von 2021 bis 2028 mit einer CAGR von 11,8 % wachsen wird.
Die zunehmende Prävalenz von Krebs und anderen chronischen Krankheiten und ein enormer Anstieg von COVID-19-Fällen in verschiedenen Bereichen Regionen sind die Schlüsselfaktoren für das Marktwachstum. Laut dem World Cancer Research Fund und dem American Institute for Cancer wurden im Jahr 2020 ~18,1 Millionen Krebsfälle registriert, darunter 9,3 Millionen Fälle bei Männern und 8,8 Millionen Fälle bei Frauen. Die Verwendung von monoklonalen Antikörpern bei der Behandlung verschiedener Krebsarten befindet sich noch in Phase-2- und Phase-3-Studien.
Strategische Erkenntnisse
Nordamerika wird seine Dominanz auf dem Markt für monoklonale Antikörper im Zeitraum 2021-2028 voraussichtlich fortsetzen. Die USA halten den größten Marktanteil in dieser Region und werden voraussichtlich im Prognosezeitraum weiterhin ein dominierender Anteilseigner auf dem Markt sein. Laut den von Globocan 2020 veröffentlichten Statistiken wurden in den USA ~1.806.590 neue Krebsfälle diagnostiziert und ~606.520 Menschen starben an dieser Krankheit. Laut einem Bericht des US-Handelsministeriums hat sein National Institute of Standards and Technology (NIST) die Finanzierung des National Institute for Innovation in Manufacturing Biopharmaceuticals in Höhe von 153 Millionen US-Dollar angekündigt. Darüber hinaus hat die FDA die Unterstützung für die Entwicklung monoklonaler Antikörper während der COVID-19-Prävalenz ausgeweitet.
Lukrative Regionen für den Markt für monoklonale Antikörper
< h3>Markteinblicke
Signifikanter Anstieg der Prävalenz von Krebs und anderen chronischen Krankheiten treibt das Marktwachstum an
Gemäß dem Bericht der American Cancer Society , lebten im Januar 2019 etwa 16,9 Millionen Menschen mit Krebs in der Vorgeschichte in den USA. Bis Januar 2030 wird die Zahl der Krebsüberlebenden allein aufgrund des Wachstums und der Alterung der Bevölkerung auf 22,1 Millionen ansteigen. Daher ist mit der zunehmenden Prävalenz von Krebs und anderen chronischen Krankheiten auch die Nachfrage nach Biologika wie monoklonalen Antikörpern (mABs) stark gestiegen. Als Hauptbestandteile vieler therapeutischer Schemata und kostengünstiger Behandlungen spielen Biologika eine Schlüsselrolle in der Krebsbehandlung.
Quellenbasierte Erkenntnisse
< p>Basierend auf der Quelle wird der Markt für monoklonale Antikörper in murine, chimäre, menschliche und humanisierte Antikörper unterteilt. Es wird geschätzt, dass das menschliche Segment im Zeitraum 2021-2028 den größten Marktanteil ausmachen wird. Das Marktwachstum dieses Segments wird auf den Anstieg aufgrund der Integration von humanen monoklonalen Antikörpern zur Behandlung verschiedener Arten von Infektionskrankheiten zurückgeführt. So brachte Regeneron beispielsweise den von der FDA zugelassenen Antikörpercocktail Casirivimab und Imdevimab zusammen zur Anwendung bei COVID-19 auf den Markt. Das Medikament hat von der FDA eine Notfallgenehmigung (EUA) erhalten. Es wird zur Behandlung von leichtem bis mittelschwerem COVID-19 bei Erwachsenen sowie bei pädiatrischen Patienten im Alter von mindestens 12 Jahren und mit einem Gewicht von mindestens 40 kg angewendet. Darüber hinaus gehören eine zunehmende Verwendung bei verschiedenen chronischen Krankheiten und der Einsatz fortschrittlicher Gentechnik zu den wesentlichen Faktoren, die das Wachstum des Marktsegments vorantreiben.
Markt für monoklonale Antikörper, nach Quelle - 2020 und 2028
Indikationsbasierte Erkenntnisse
Basierend auf Indikation, Krebs, Autoimmunerkrankungen, entzündlichen Erkrankungen, Infektionskrankheiten, mikrobiellen Erkrankungen, und andere. Das Krebssegment werde in den kommenden Jahren den Markt dominieren. Fortschritte im Zusammenhang mit der therapeutischen Anwendung von monoklonalen Antikörpern haben ihre erfolgreiche Implementierung bei der Behandlung verschiedener Krebsarten wie Brustkrebs, Lungenkrebs und Dickdarmkrebs ermöglicht. Auf diesen Antikörpern basierende Medikamente helfen dabei, Krebszellen zu erkennen, die Zerstörung von Zellmembranen auszulösen, Hemmstoffe des Immunsystems zu blockieren und so weiter. Die FDA hat im Juni 2020 zwei Medikamente - Olaparib und Rucaparib - zur Behandlung von Prostatakrebs zugelassen. Das Medikament ist besonders wirksam bei Männern mit Prostatakrebserkrankungen, die sich ausgebreitet oder metastasiert haben und nicht mehr auf herkömmliche Hormonbehandlungen ansprechen, dh kastrationsresistente Erkrankungen.
Endverbraucher- Basierend auf Erkenntnissen
Der Markt für monoklonale Antikörper ist nach Endverbrauchern in Krankenhäuser, Forschungsinstitute und andere unterteilt. Das Krankenhaussegment hält den größten Marktanteil aufgrund der zunehmenden Einführung von mABs als bevorzugte Behandlungslinie, insbesondere für die Krebsbehandlung.
< p>Unternehmen, die auf dem Markt für monoklonale Antikörper tätig sind, übernehmen die Produktinnovationsstrategie, um den sich entwickelnden Kundenanforderungen auf der ganzen Welt gerecht zu werden, was es ihnen auch ermöglicht, ihren Markennamen auf dem globalen Markt zu behaupten.
Markt für monoklonale Antikörper - Segmentierung
Basierend auf der Quelle wird der Markt für monoklonale Antikörper in human, humanisiert, chimär und murin unterteilt. Nach Herstellungsverfahren wird der Markt in In-vitro und In-vivo unterteilt. Der Markt für monoklonale Antikörper ist nach Indikation weiter unterteilt in Krebs, Autoimmunerkrankungen, Infektionskrankheiten, entzündliche Erkrankungen, mikrobielle Erkrankungen und andere. Nach Anwendung wird der Markt in therapeutische Anwendungen, diagnostische Anwendungen und Forschungsanwendungen unterteilt. Darüber hinaus ist der Markt basierend auf dem Endverbraucher in Krankenhäuser, andere und Forschungsinstitute unterteilt.
Markt für monoklonale Antikörper - nach Geografie
- Nordamerika
- USA
- Kanada
- Mexiko
- Europa
- Frankreich
- Deutschland
- Italien
- Großbritannien
- Spanien
- Rest von Europa
- Asien-Pazifik (APAC)
- China
- Indien
< li>Südkorea - Japan
- Australien
- Rest von APAC
- Südafrika
- Saudi-Arabien
- VAE
- Rest von MEA
- Brasilien
- Argentinien
- Rest von SCAM
Unternehmensprofile
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Eingeschränkt
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lily and Company
- Bayer AG
< li>Bristol-Myers Squibb Company
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.
Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market
The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.
Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.
Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.
Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The List of Companies - Monoclonal Antibody Market
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Limited
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2022
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jan 2022
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2022
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jan 2022
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Jan 2022
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Jan 2022
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Jan 2022
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)